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Abstract
Delivery systems designed to have triggered release after passively targeting the tumor may
improve small molecule chemotherapeutic delivery. Particle replication in nonwetting templates
was used to prepare nanoparticles to passively target solid tumors in an A549 subcutaneous
xenograft model. An acid labile prodrug was delivered to minimize systemic free docetaxel
concentrations and improve tolerability without compromising efficacy.
Keywords
Soft-lithography; docetaxel; polylactic acid; silyl ether
The synthesis of prodrugs is a common approach to overcome drug delivery issues,
including poor aqueous solubility1 or permeability,2 and to provide site-specific release.3
Nanotechnology can be a powerful tool to improve drug delivery, but does so by altering the
biodistribution of the encapsulated small molecule.4,5 In this report, we combined the merits
of both approaches to improve the pharmacokinetics and toxicity of the chemotherapeutic
docetaxel by passively targeting an encapsulated docetaxel prodrug to solid tumors, where it
could selectively release and convert to active docetaxel.
Many chemistries have been utilized to prepare prodrugs of taxanes6–9 or
camptothecins.10,11 Hydrazone bonds cleave quickly at acidic conditions, but derivatives of
taxanes must first be synthesized to accommodate this chemistry.8 Thus, free paclitaxel or
docetaxel is not released immediately after the hydrazone bond cleaves. Many of these other
linkers were too stable in vivo and did not release the active therapeutic at high
concentrations.6,11 Insufficient prodrug conversion may hinder therapeutic efficacy because
the active compound never reaches therapeutically relevant concentrations. Ester prodrugs,
though more common in usage for prodrugs, do not offer fast conversion within the tumor
microenvironment.9 Amino acid linkers were found to cleave more rapidly at higher pH
values, but the tumor microenvironment is thought to be acidic.10,11 Thus, a linker with
triggered release at basic conditions may not be preferable for chemotherapeutic delivery.
Utilization of the endosomal enzyme cathepsin B has been used with success for targeted
delivery systems12 but has yielded mixed results for non targeted polymer drug conjugates.
Retrospective analysis of phase III clinical trial results of a cathepsin B sensitive polymer
drug conjugate suggested that different levels of cathepsin B activity may lead to differences
in survival.13 For this work, we selected a prodrug chemistry with established tunability to
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ensure active drug release at the target site.14 There are no known enzymes that degrade silyl
ethers, thus the use of this chemistry may ensure that the drug is only released within more
acidic environments. Chlorosilanes with different combinations of steric bulk and alkyl
chain lengths are commercially available to synthesize prodrugs with varying rates of
hydrolysis, water solubility, and affinity to the particle matrix in order to control drug
release rates. Alkyl silyl ether prodrugs of docetaxel were synthesized for incorporation into
poly(lactide-co-glycolide) nanoparticles prepared by the particle replication in nonwetting
templates (PRINT) process. The increased lipophilicity of the prodrug improved drug
retention in the particles, which delayed the release of the prodrug until the particles
passively targeted the solid tumor.
Prodrug Synthesis and Particle Fabrication
The silyl ether docetaxel prodrugs, C2 (ethyldimethylsilyl ether docetaxel) and C8
(octyldimethylsilyl ether docetaxel), were prepared by a single step reaction of docetaxel
with chlorodimethyle-thylsilane or chloro(dimethyl) octylsilane, respectfully (Scheme 1). It
has been well documented that the C2’ alcohol of taxanes preferentially react with
electrophiles, such as acid chlorides and anhydrides.15,16 As expected, the C2’
monosubstituted silyl ether prodrugs of docetaxel formed and were isolated in good yield.
The rate of conversion of the prodrug to docetaxel is the consequence of simple hydrolysis
and can be tuned by altering the substituents on the silicon atom. To achieve rapid prodrug
hydrolysis upon release from the NP, alkyl dimethyl silyl chlorides were selected (Figure
1A,B). Hydrolysis of the prodrugs was evaluated in aqueous solutions at different pH
conditions (pH 5 and pH 7) and 37 °C in the presence of human serum albumin and
measured by LC-MS/MS. At pH 5, the C2 prodrug was quickly degraded; full conversion
was achieved at 6 h (Figure 1A), where as the C8 prodrug was not fully converted until 24 h.
The conversion of the prodrugs to docetaxel was also studied in mouse plasma at
physiological conditions. The t1/2 of C2 and C8 in mouse plasma were similar, 8 h for the
C2 prodrug and 10 h for the C8 prodrug. The majority of the C2 and C8 prodrugs are
converted within the first 24 h. The toxicity of C2 and C8 were compared to free docetaxel
in vitro in A549 cells (Figure 1C). With a 24 h incubation time, the toxicity of the C2 and
C8 prodrugs were less than that of free docetaxel. Modification of the C2’ alcohol of taxanes
reduces its activity and requires conversion of the prodrug to achieve efficacy.7
Cylindrical particles with diameter (d) = 80 nm and height (h) = 320 nm were prepared
using a poly(lactide-co-glycolide) polymer. By dynamic light scattering (DLS), the
hydrodynamic radius was measured as ~200 nm. The particle samples were monodisperse
with a polydispersity index (PDI) of less than 0.1 and as low as 0.05. PRINT NPs were
loaded with drugs at weight percents of 20–22%. NP formulations of docetaxel and two
docetaxel prodrugs, C2 and C8, were prepared. All formulations were similar in particle size
and drug loading (Table 1). The release kinetics of the three formulations, DTXL-NP
(docetaxel nanoparticle), C2-NP, and C8-NP, were evaluated at 37 °C in phosphate-buffered
saline (Figure 1D). Release kinetics were dependent upon the length of the alkyl chain of the
docetaxel prodrug; prodrugs with the longer alkyl chain lengths had slower release from the
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particles. Unmodified docetaxel was fully released after 24 h where as the C2 prodrug was
fully released after 4 days and C8 prodrug was not fully released after 7 days.
In Vivo Pharmacokinetics of Prodrug NPs
The pharmacokinetic parameters and profiles of DTXL-NP and C2-NP, the two faster-
releasing formulations, compared to free docetaxel at equal-molar dosing are shown in
Figure 2 and Table 2. Mice with A549 flank tumors were administered one dose at 10 mg/kg
docetaxel via vein injection and subsequent drug concentrations were measured in plasma,
tumor and tissue by LC-MS/MS. All NP formulations had greater sum total plasma
exposures (encapsulated docetaxel or prodrug + released docetaxel) compared to free
docetaxel when measured by the area under the concentration − time curve (AUC). A 60-
fold increase in AUC was realized for the DTXL-NP where as the C2-NP formulations
displayed a 182-fold in AUC. The improved sum total plasma AUC of the C2-NP relative to
the DTXL-NP may be attributed to the slower release kinetics of the C2 prodrug. The
improved retention of the C2 prodrug in the NPs most likely reduced the tissue distribution
of C2 as evidenced by the reduced Vd of sum total C2 compared to sum total docetaxel (237
vs 4513 mL/kg). Comparison of the sum total Cmax also suggests that improved NP
retention of drug reduces immediate tissue distribution. The order of Cmax from least to
highest for the NP formulations emulated the in vitro release kinetics, docetaxel and C2 (23
359 ± 4528 vs 78 952 ± 6589, P = 0.0002). Furthermore, minimal conversion of C2
docetaxel was observed in plasma of the total drug (Figure 1A). The percentage of released
docetaxel from C2-NP was 2.3%. This percentage was calculated by AUCC2/
(AUCC2+AUCDTXL) × 100.
In vitro, the C2 had a short conversion half-life of 8 h; the NP likely protects the prodrug in
plasma to prevent conversion before the prodrug reaches the target site of the tumor. This
design attribute has the potential to decrease systemic toxicity of chemotherapeutics.
Though low C2 plasma conversion is preferred, the prodrug must convert at its target site to
be effective. 32.5% of C2 was determined to be converted to docetaxel in the tumor, much
higher than the 2.3% observed within the plasma. This percentage compares favorably to
other polymeric prodrug strategies that have entered clinical development. For a
camptothecin polymer drug conjugate, only 1.3% unconjugated camptothecin was observed
in xenograft tumors over 48 h.11 Only 4–17% of unconjugated paclitaxel from a paclitaxel
polymer drug conjugate was observed in a xenograft tumors over 144 h.6 In other tissues
where the NPs distribute, the liver and spleen (Supporting Information Figure 1 and Table 1)
only had 13.2 and 2.7% free docetaxel from C2. The silyl ether prodrug has selective
conversion at the target site of the tumor. Silyl ethers are commonly used as protecting
groups that are acid-labile.17 The hypothesized acidic tumor microenvironment is thought to
contribute to the site selective conversion.
In Vivo Efficacy and Tolerability
The efficacy of the C2-NP formulation was compared to free docetaxel in an A549
subcutaneous xenograft mouse model. Mice were administered weekly doses via tail vein
injection over 6 weeks. Figure 3A shows the tumor growth curves for free docetaxel at its
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MTD18(20 mg/kg), C2-NP at 20 mg/kg, and C2-NP at its MTD of 50 mg/kg. The final
relative tumor volume of mice receiving C2-NP was equal to free docetaxel when
administered at 20 mg/kg. However, at 50 mg/kg, mice receiving the C2-NP had statistically
lower mean relative tumor volume than mice receiving free docetaxel at 20 mg/kg starting at
day 10. Body weights (Figure 3B) of mice receiving saline and equimolar doses of free
docetaxel and C2-NP remained stable over the course of treatment, while some body weight
loss was observed in mice receiving the 50 mg/kg dose of C2-NP over the course of 6 doses.
On the basis of the pharmacokinetic profile of the tumor, mice receiving C2-NP at equal
molar dosing to free docetaxel did not have increased sum total docetaxel concentrations
(Figure 1B). The similar tumor docetaxel levels may explain the similar tumor growth rates
for mice receiving C2-NP and free docetaxel at equal molar doses.
However, the C2-NP formulation improved the tolerability of docetaxel in mice.
Neutropenia, characterized by reduced white blood cell counts (WBC), is a common side
effect of docetaxel (Taxotere). Patients that experience dose limiting toxicity due to
neutropenia may benefit from different dosing schedules, such as receiving doses every 2
weeks versus 3 weeks, but this may be inconvenient to the patient.19 Thus, a formulation
change to improve the toxicity profile of docetaxel is an attractive option. Table 3 shows the
mean white blood cell counts of mice receiving the C2-NP (20 mg/kg or 50 mg/kg)
compared to free docetaxel (20 mg/kg). Blood was collected 4 days after injection and
measured for complete blood counts. Mice receiving the C2-NP formulation at an equal
molar dose to free docetaxel trended toward statistically higher WBC 4 days after the first
dose (P = 0.12) and almost double the WBC 4 days after the sixth dose (P = 0.008). The
pharmacokinetic data demonstrates that only a fraction of C2 is converted to docetaxel
within the plasma, liver and spleen. The minimized free docetaxel concentrations likely
account for the improved tolerability of the C2-NP. With improved tolerability, mice could
receive a 2.5 times higher docetaxel dose with the C2-NP than free docetaxel, resulting
tumor reduction in the efficacy study.
Compared to poly(lactide) docetaxel NPs in clinical development, release of docetaxel
directly from NPs has not shown improvement in tolerability relative to the clinical control
Taxotere.20,21 Nanoxel-PM is a micelle formulation of docetaxel, consisting of PDLLA-
mPEG. In preclinical models, Nanoxel-PM had similar pharmacokinetics to Taxotere and a
similar hematological toxicity profile.20 Instability of the micelle may be a potential reason
why an improved toxicity profile was not observed. However, BIND-014 is a stable targeted
PLA-PEG nanoparticle with controlled release of docetaxel and differentiated
pharmacokinetics and efficacy.21 Even with these improved attributes, BIND-014 did not
achieve a higher maximum tolerated dose than Taxotere in a phase I clinical trial.21 Thus,
unlike reformulations of paclitaxel, where removing cremophor EL as an excipient
contributed to increased tolerability,22 there has yet to be a formulation change that
improves the hematological toxicity of docetaxel in a clinical setting. Our prior data that
evaluated PLGA docetaxel particles in vivo also did not improve the hematological toxicity
of docetaxel compared to Taxotere, even though the maximum tolerated dose was increased
by 50%.18 Thus, the use of a prodrug strategy appears to be key in improving the toxicity
profile of docetaxel by reducing the amount of docetaxel in systemic circulation.
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We have demonstrated that combining a labile prodrug of docetaxel with NP delivery
improves the tolerability of docetaxel without decreasing efficacy by minimizing systemic
conversion of the prodrug but preferential converting within the tumor. Further work is
being conducted to more thoroughly identify the appropriate dose level to balance efficacy
and toxicity.
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(A) Hydrolysis of prodrugs in pH 5 and pH 7 buffer at 37 °C. (B) Hydrolysis of prodrugs in
mouse plasma at physiological conditions. (C) Cytotoxicity of docetaxel, C2 and C8 on
A549 cells in vitro. (D) Release kinetics of docetaxel, C2 and C8 from PLGA NPs at pH 7.4
and 37 °C.
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Pharmacokinetic profiles of the following: red circle, free docetaxel; gray square, DTXL-
NP; and green diamond, C2-NP formulations (dotted line indicates C2 prodrug and solid
line indicates converted DTXL). Each replicate is shown and lines are connected by the
means of three replicates at each time point. Mice bearing A549 flank tumors received one
iv injection via tail vein at 10 mg/kg docetaxel or docetaxel molar equivalents.
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(A) Tumor growth inhibition curve (mean ± sem). Mice bearing A549 flank tumors received
6 weekly doses via IV tail vein injection. Black circle, saline; red square, free docetaxel (20
mg/kg); gray triangle up, C2-NP (20 mg/kg dtxl equivalents); and blue triangle down, C2
NP (50 mg/kg dtxl equivalents) Mice receiving C2 NP at 50 mg/kg had tumor volumes
lower than mice receiving free docetaxel (P < 0.05 starting on day 10). (B) Body weights
(mean ± std dev). Twenty mg/kg weekly × 6 is the maximum tolerated dose for docetaxel in
this model.18
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Synthesis of Alkyl Silyl Ether Docetaxel Prodrugs
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Table 1
NP Characterization of DTXL-NP, C2-NP and C8-NP Formulations
formulation size (nm) PDI zeta potential (mV) weight percent loading
DTXL-NP 213 ± 1 0.07 ± 0.01 −2.81 ± 0.23 21.2 ± 0.5
C2-NP 205 ± 2 0.05 ± 0.02 −2.65 ± 0.52 20.7 ± 0.4
C8-NP 208 ± 7 0.09 ± 0.02 −3.78 ± 0.36 22.3 ± 1.9















































































































































































































































































Chu et al. Page 14
Table 3
White Blood Cell Counts Measured 4 Days after Injection with Saline, Free Docetaxel or C2-NP at Two Dose
Levels
time point saline free docetaxel (20 mg/kg) C2-NP (20 mg/kg) C2-NP (50 mg/kg)
WBC (103 cells/μL)
day of dose 1 2.07 ± 0.21 1.34 ± 0.36 1.67 ± 0.54 1.54 ± 0.35
4 days after dose 1 2.81 ± 0.91 c0.84 ± 0.65 a,c1.41 ± 0.65 c0.49 ± 0.38
4 days after dose 6 3.43 ± 1.13 c1.53 ± 0.52 b3.00 ± 1.10 c0.56 ± 0.28
a
Indicates trend toward statistically significance compared to free docetaxel (P = 0.12).
b
Indicates statistical significance compared to free docetaxel (P = 0.008).
c
Indicates statistical significance compared to saline (P < 0.006).
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